BERLIN--(BUSINESS WIRE)--INJEX Pharma AG is pleased to announce that the German Federal Financial Supervisory Authority (BaFin) approved yesterday the share prospectus of the company. The prospectus is from now on available on the Company's website at www.injex.com.
INJEX Pharma aims to achieve a listing on the regulated market of the Frankfurt Stock Exchange (segment General Standard) - an approved prospectus by BaFin is a precondition. A stock exchange listing on the regulated market is delivering increased visibility on the capital markets for the company and is part of the implementation of the growth strategy. The desired listing in General Standard will broaden the shareholder base of the company even more and will make it easier to trade the shares for international investors.
The admission of shares is expected on March 11, 2013 in the regulated market of the Frankfurt Stock Exchange in the General Standard segment. The listing is expected on March 18, 2013. A change of this timetable is still possible. The securities code number of the shares is ISIN: DE000A0STYL7, the WKN number is WKN: A0STYL.
For further information on INJEX Pharma AG and its subsidiaries, please refer to www.injex.com.
INJEX Pharma AG:
INJEX Pharma Aktiengesellschaft and its subsidiaries INJEX Pharma GmbH and INJEX Vertrieb Deutschland GmbH are specialized in the development, manufacturing and marketing in the medical technology segment and in the cosmetics and beauty markets. The Group's core business areas are the needle-free INJEX30 system and the product line SHIREEN in the beauty market. The main markets of the Group are North America, China, India, Russia and Europe.
End of Corporate News